---
layout: default
title: Activated Charcoal Arsenic Triiodide Causticum Cup
parent: 僅模型預測 (L5)
nav_order: 208
evidence_level: L5
indication_count: 0
---

# Activated Charcoal Arsenic Triiodide Causticum Cup
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Ingredient Homeopathic Compound: Repurposing Evaluation Not Possible

## One-Sentence Summary

This entry contains a nine-ingredient combination — including Activated Charcoal, Arsenic Triiodide, Causticum, Cupric Acetate, Drimia Maritima Bulb, Drosera Rotundifolia, Lachesis Muta Venom, Potassium Carbonate, and Protortonia Cacti — consistent with a homeopathic/alternative medicine formulation.
The TxGNN model **did not generate any predicted indications** for this compound, most likely because no DrugBank ID could be matched and the multi-ingredient structure cannot be mapped to the knowledge graph as a single entity.
As a result, **no evidence of any level** is available to support a repurposing direction.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available (no approved indications on record) |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | Below L5 (no prediction, no studies) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No prediction was generated, so a mechanistic justification cannot be written.

For context, the nine listed ingredients are consistent with classical homeopathic repertory formulations:

- **Drosera rotundifolia** is frequently cited in homeopathic materia medica for spasmodic cough and pertussis-like symptoms.
- **Drimia maritima (sea squill)** has a long ethnopharmacological history as a cardiac glycoside source and expectorant.
- **Lachesis muta venom** and **Potassium Carbonate (Kali Carb)** are classical homeopathic polychrests used across a wide range of constitutional and respiratory presentations.
- **Arsenic Triiodide** and **Causticum** are diluted homeopathic preparations; their pharmacological activity at homeopathic dilutions is not established in the conventional sense.

Because DrugBank does not maintain records for multi-ingredient homeopathic mixtures at this level of specificity, the TxGNN knowledge graph has no node to anchor a prediction. No mechanism of action data is available.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note on Arsenic Triiodide:** Even at low concentrations, inorganic arsenic compounds carry regulatory toxicity concerns. If this product is reformulated or investigated at pharmacologically active doses, a dedicated toxicological review will be required before any clinical use.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This compound is a multi-ingredient homeopathic mixture with no DrugBank ID, no approved indication, no US market presence, and no TxGNN prediction. The evidence framework required for a repurposing evaluation does not exist for this entry.

**To proceed, the following is needed:**

- **Establish drug identity:** Determine whether this combination is sold as a finished product with a known brand name, lot number, or pharmacopoeia reference (e.g., HPUS, HAB, or Ph.Eur. homeopathic monographs).
- **Assign a lead ingredient:** If the intent is to evaluate a single active component (e.g., Drimia maritima glycosides, or arsenic trioxide at oncological doses), the evaluation must be rerun as a single-INN query with a valid DrugBank ID.
- **Clarify regulatory scope:** Homeopathic combinations are exempt from standard NDA pathways in most jurisdictions; confirm whether conventional drug repurposing methodology is the appropriate framework for this product.
- **Obtain MOA data:** If any single ingredient in this mixture has a documented pharmacological mechanism, retrieve it via DrugBank API before resubmitting.
- **Safety assessment:** Retrieve package insert or TFDA product dossier to complete the baseline safety profile, particularly regarding the arsenic and venom components.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

